Clinical Trials Browser

Breast Neoplasms × radium Ra 223 dichloride × Clear all

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast Neoplasms

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase 2 Completed

45 enrolled 7 charts

Breast Neoplasms

NCT02258464 2020-08-10

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Terminated

99 enrolled 18 charts

Breast Neoplasms

NCT01070485 2014-06-25

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Phase 2 Completed

Breast Neoplasms